Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Aug 17;90(31):2212-4.

[A comparative study of survival time of surgery combined with chemotherapy and non-surgical chemotherapy in SCLC]

[Article in Chinese]
Guang-hu Li  1 , Yong Wu, Xiong-ji Zhang, Yong-sheng Cui
Affiliations
  • PMID: 21029664
Comparative Study

[A comparative study of survival time of surgery combined with chemotherapy and non-surgical chemotherapy in SCLC]

[Article in Chinese]
Guang-hu Li et al. Zhonghua Yi Xue Za Zhi. .

Abstract

Objective: To compare the survival time of surgery combine with chemotherapy with non-surgery chemotherapy in SCLC.

Methods: 37 SCLC post operation patients were received 4-6 cycles of chemotherapy of "etoposide + cisplatin or carboplatin". 37 SCLC patients were selected be control group, whose age, stage and site of tumor were similar to surgery combine with chemotherapy group, and received 6 cycles of chemotherapy of "etoposide + cisplatin or carboplatin". Two groups were followed up 5 year and compared with the survival time.

Results: The 1, 3, 5 year survival rate of surgery combined with chemotherapy group were 72.97%, 35.13%, 21.62%. The 1, 3, 5 year survival rate of control group were 54.05%, 13.51%, 5.41%. The survival rate of stage I (P = 0.01) was significantly different, but stage II (P = 0.06) and stage III (P = 0.836) were no difference between the two group of SCLC.

Conclusion: It was found that surgery combined with chemotherapy got satisfactory effects in stage I SCLC.

PubMed Disclaimer